P/B
2,5
QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
$8.8B
Market Cap • 9/11/2026
1980
(46 years)
Founded
1996
(30 years ago)
IPO
NYSE
Listing Exchange
Netherlands
Country
Valuation
P/S
4,2
P/EBITDA
13,4
P/OCF
13
P/FCF
19
P/E
21,8
BVPS
16,3
EPS
2
Market Cap
Market Cap
8,8B
EV
9,4B
EV/Revenue
4,5
EV/EBITDA
14,4
EV/EBIT
21,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,3%
Total Yield
0,3%
Dividend Yield 5Y
0,1%
Payout
0%
Retained Earnings
2,8B
Profitability
Gross Margin
62,2%
EBITDA Margin
31,1%
EBIT Margin
21,2%
Net Margin
19,5%
D&A/EBITDA
1,4%
R&D/Revenue
9,3%
Capex/Revenue
10,2%
Capex/D&A
103,1%
Capex/OCF
31,7%
SBC/OCF
6,5%
% PPE
11,1%
% Goodwill
45,6%
ROE
11,7%
ROIC
9,7%
Growth
CAGR Revenue 5Y
-0,8%
CAGR Op. Income 5Y
-3,3%
CAGR Net Income 5Y
-3,1%
CAGR EPS 5Y
-3,2%
CAGR OCF 5Y
3,2%
Leverage
N.D./EBITDA
1
Debt/Equity
0%
Current Ratio
2,8
Quick Ratio
2
Interest Coverage
1129,7%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!